Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the initiation of a public offering of up to 8,000,000 shares of common stock, along with Class E and Class F common warrants to purchase additional shares. The offering also includes pre-funded warrants to purchase shares of common stock. The event is aimed at raising capital to support the continued clinical development of Panbela's lead product candidates, including ivospemin for pancreatic cancer and Flynpovi for familial adenomatous polyposis (FAP). The offering is being managed by Roth Capital Partners, LLC as the lead placement agent on a best-efforts basis. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'PBLA'. Panbela's management has entered...Show More

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the initiation of a public offering of up to 8,000,000 shares of common stock, along with Class E and Class F common warrants to purchase additional shares. The offering also includes pre-funded warrants to purchase shares of common stock. The event is aimed at raising capital to support the continued clinical development of Panbela's lead product candidates, including ivospemin for pancreatic cancer and Flynpovi for familial adenomatous polyposis (FAP). The offering is being managed by Roth Capital Partners, LLC as the lead placement agent on a best-efforts basis. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'PBLA'. Panbela's management has entered into lock-up agreements restricting the sale of their shares post-offering. The company has also outlined the potential use of proceeds, which includes funding for clinical trials, regulatory approvals, and general corporate purposes. The offering is subject to market conditions, and there is no assurance that it will be completed or that the intended amount of capital will be raised.